← Eichor
Condition: Alk Non Small Cell Lung Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Alk Non Small Cell Lung Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT04322890Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Ef
Phase 2 · 1 location(s) · Xinqiao Hospital of Chongqing · NCT06953843Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
Phase N/A · 1 location(s) · Pfizer · NCT05599412Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
Phase N/A · 1 location(s) · Jinming Yu · NCT05991895Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres
Phase 2 · 27 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT06620835A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · 296 location(s) · AstraZeneca · NCT06868277Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06234579A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 287 location(s) · AstraZeneca · NCT06627647ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05014464Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07354061A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment o
Phase 2 · 1 location(s) · Xinqiao Hospital of Chongqing · NCT06947694QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
Phase 2 · 1 location(s) · Anhui Provincial Cancer Hospital · NCT07330596Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Phase 1/Phase 2 · 12 location(s) · TRIANA Biomedicines, Inc. · NCT07491497Gilteritinib for the Treatment of ALK NSCLC
Phase 1 · 3 location(s) · University of Michigan Rogel Cancer Center · NCT06225427Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Phase 2 · 1 location(s) · Guangdong Association of Clinical Trials · NCT06092086A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Phase N/A · 1 location(s) · Peking University Shenzhen Hospital · NCT07374614A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Ther
Phase N/A · 44 location(s) · Hoffmann-La Roche · NCT06862869Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Phase 4 · 8 location(s) · University Medical Center Groningen · NCT05525338Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Pingping Song · NCT05765877Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World C
NA · 31 location(s) · Pfizer · NCT06487078Patient-centered, Optimal Integration of Survivorship and Palliative Care
NA · 1 location(s) · Massachusetts General Hospital · NCT04900935
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.